Opus Genetics Financials - Benzinga

Opus Genetics Inc

IRDNASDAQ

Trade with Public

Trade with Public

$6.13

0.0550.91%

Last update: Sep 11, 3:14 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Opus Genetics Financials

Opus Genetics (IRD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.14) by 435.71 percent. This is a 212.5 percent decrease over losses of $(0.24) per share from

Benzinga Newsdesk

Earnings Summary: Opus Genetics Q4

Benzinga Insights

PRO
Opus Genetics Q4 EPS $(0.21) Misses $(0.12) Estimate, Sales $3.865M Beat $3.649M Estimate

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 70.73 percent. This is a 83.46 percent increase over losses of $(1.27) per share from

Benzinga Newsdesk

PRO
Opus Genetics Q3 EPS $(0.25) Misses $(0.13) Estimate, Sales $3.079M Beat $3.075M Estimate

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.13) by 92.31 percent. This is a 13.79 percent increase over losses of $(0.29) per share from

Benzinga Newsdesk